CMTRF funded partner 82VS, the Venture Studio of Alloy Therapeutics, is looking to solve one of the toughest problems in Charcot-Marie-Tooth disease: getting RNA-based therapies to the peripheral nerves and cells damaged by CMT.

This project uses specially designed antibodies to guide RNA therapies directly to nerve cells, and if successful, could open the door to an entirely new class of treatments for CMT1A and lay the groundwork for therapies that help many other forms of CMT. Join us Thursday, December 11, at 7 p.m. ET via Zoom, as Dr. Carlos Loya and the CMTRF team walk through the challenge of delivering treatments to nerves, share early encouraging results from this CMTRF-funded project, and discuss what this approach could mean for the future of CMT care. There is no cost to attend. To register, visit https://cmtrf.org/webinars/